News & Updates
Filter by Specialty:
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
Nursing interventions boost sexual QoL of breast cancer patients
Nursing interventions such as psychological and educational assistance help improve the sexual quality of life (QoL) among patients with breast cancer, reports a recent study.
Nursing interventions boost sexual QoL of breast cancer patients
10 Nov 2022
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
In patients with non-muscle-invasive bladder cancer (NMIBC), high-grade (HG) recurrence after bacillus Calmette-Guérin (BCG) treatment is associated with T-cell exhaustion, according to a study.
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
07 Nov 2022
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.
